In the United States alone, 1.25 million people suffer from type 1 diabetes. A vaccine used over 100 years ago for tuberculosis (bacillus Calmette-Guerin ) has shown promise in reversing this disease. This vaccine is now commonly used for treating bladder cancer and is considered to be safe.
An announcement made yesterday at the 75th Scientific Sessions of the American Diabetes Association said that the FDA will test the vaccine on 150 people who are in an advanced stage of type one diabetes.
The body of a man with sort 1 diabetes does not deliver insulin because of the safeframeworkwrecking thecells that make insulin .Immune system microorganisms are delivered ,and these cellsmake issues in thepancreatic islet’s , where insulin is created . The antibody worksby wiping outthese White blood cells . Patientswith diabetes infused with the immunization sawan expansion ofthe levels of a substance called tumorputrefaction component . The expandedlevel of TNF in theframework devastates the Immune systemmicroorganisms that are preventingthe creation of insulin. In a past trial , patients were infused with thetuberculosis immunizationtwice inside a four-weektimes the span . The outcomes demonstrated thatthe hazardous Whiteblood cells were gone , and a few people even started to emit insulin all alone ..
Dr. Denise Faustman, director of the Massachusetts General Hospital Immunobiology Laboratory in Boston, is very excited about the results the BCG vaccine has been showing.
“In the phase I (preliminary) trial we demonstrated a statistically significant response to BCG, but our goal in (this trial) is to create a lasting therapeutic response. We will be working again with people who have had type 1 diabetes for many years. This is not a prevention trial; instead, we are trying to create a regimen that will treat even advanced disease.”
This new five-year trial will begin this late spring . The individuals that are selected will extend for over agesfrom 18 to 60-years of age . The trial will utilize the same configuration as wasutilizedbefore by infusingpatients twice inside a four-week times frame . Patients will then haveone infusiona year for the following fouryears .
Not all diabetes experts are confident that this treatment will work. Robert Sobel, an assistant professor of endocrinology at Northwestern University’s Feinberg School of Medicine, explains why he is skeptical.
“I think it’s a stretch to say this would have a huge impact on the millions plus type I diabetes patients in this country. We would love to do something to preserve or repopulate their beta cell mass. Historically, we have watched it dwindle and have not been able to do something (in time).”
Time will tell if this vaccine will become a viable treatment option for type 1 diabetes or not.